Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin

This publication has 23 references indexed in Scilit:

• Synthetic Triterpenoids Cooperate with Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand to Induce Apoptosis of Breast Cancer Cells
  Cancer Research, 2005
• HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
  British Journal of Cancer, 2005
• Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
  The Lancet Oncology, 2004
• The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-γ Ciglitazone Affects Human Glioblastoma Cell Lines
  The Journal of Pharmacology and Experimental Therapeutics, 2004
• An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis
  Journal of Biological Chemistry, 2002
• Selective Expression of FLIP in Malignant Melanocytic Skin Lesions
  Journal of Investigative Dermatology, 2001
• Increased expression of cFLIPL in colonic adenocarcinoma
  The Journal of Pathology, 2001
• Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity
  Biochemical and Biophysical Research Communications, 1999
• Safety and antitumor activity of recombinant soluble Apo2 ligand
  Journal of Clinical Investigation, 1999
• APO2 ligand: a novel lethal weapon against malignant glioma?
  FEBS Letters, 1998